The OsteoPearl biologic allograft is made from 100% cortical bone and is designed to stabilize vertebral compression fractures, according to a May 9 news release. The investment will also expand clinical evidence and support development.
Xcellerant Ventures, Highpoint Ventures, Vodia Capital, RightHill Ventures and other groups were involved with funding.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.